Clinical Trial: A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)

U.S., Feb. 13 -- ClinicalTrials.gov registry received information related to the study (NCT06821334) titled 'A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)' on Feb. 10.

Brief Summary: The goal of this study is to learn how safe MK-6194 is in healthy Chinese adults and how well people tolerate it.

Study Start Date: April 23, 2024

Study Type: INTERVENTIONAL

Condition: Healthy

Intervention: BIOLOGICAL: MK-6194

Subcutaneous Administration

BIOLOGICAL: Placebo

Subcutaneous administration

Recruitment Status: COMPLETED

Sponsor: Merck Sharp & Dohme LLC

Published by HT Digital Content Services with permission from Health Daily Digest....